Page last updated: 2024-10-23

bethanechol and Cancer of the Thyroid

bethanechol has been researched along with Cancer of the Thyroid in 2 studies

Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.
bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Campanhã, D1
PereiraLIMA, EN1
Alves, FA1
Jaguar, GC1
Auttara-Atthakorn, A1
Sungmala, J1
Anothaisintawee, T1
Reutrakul, S1
Sriphrapradang, C1

Reviews

1 review available for bethanechol and Cancer of the Thyroid

ArticleYear
Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adenocarcinoma; Amifostine; Bethanechol; Humans; Iodine Radioisotopes; Pilocarpine; Randomized Contr

2022

Trials

1 trial available for bethanechol and Cancer of the Thyroid

ArticleYear
Bethanechol used to prevent salivary gland dysfunction in patients submitted to radioactive iodine therapy: A double blind, placebo-controlled, randomized study.
    Journal of stomatology, oral and maxillofacial surgery, 2022, Volume: 123, Issue:5

    Topics: Bethanechol; Humans; Iodine Radioisotopes; Quality of Life; Salivary Glands; Thyroid Neoplasms; Xero

2022